United States News Todas as matérias

BrainsWay (NASDAQ:BWAY) delivered a powerful first-quarter 2026 performance, marked by a 35% year-over-year revenue increase to $15.5 million.

Altimmune (NASDAQ:ALT), a clinical-stage biopharmaceutical company developing treatments for metabolic and liver diseases, reported its first-quarter 2026 financial results and provided a business update.

Nexxen International (NASDAQ:NEXN), a global advertising technology platform, reported record-breaking financial results for the first quarter of 2026.

Kornit Digital (NASDAQ:KRNT), a leading provider of digital textile printing technology, announced its first-quarter 2026 financial results.

Caesarstone (NASDAQ:CSTE) reported first-quarter 2026 results that highlighted the early fruits of its structural reorganization.

Beasley Broadcast Group (NASDAQ:BBGI) reported a complex first quarter for 2026, where a return to statutory profitability was accompanied by persistent headwinds in traditional agency advertising.

Similarweb (NYSE:SMWB) reported a significant improvement in its financial health for the first quarter of 2026, swinging to a non-GAAP operating profit as the company scales its footprint among high-value enterprise clients.

Dominari Holdings (NASDAQ:DOMH) revealed a massive acceleration in its business for the first quarter of 2026, fueled by a resurgence in investment banking and underwriting activity.

Riskified (NYSE:RSKD) reported first-quarter 2026 financial results that showcased resilient demand for its AI-driven fraud management platform.

Eos Energy Enterprises (NASDAQ:EOSE) kicked off fiscal year 2026 with an aggressive acceleration in manufacturing output and a transformative strategic partnership.

Dynatrace (NYSE:DT) announced record financial results for its fourth quarter and full fiscal year 2026, officially surpassing the $2 billion mark in annual recurring revenue (ARR).

Voyager Therapeutics (NASDAQ:VYGR) achieved a critical regulatory milestone this week, presenting positive three-month toxicology data for its lead Alzheimer’s disease candidate, VY1706.

Global-e Online (NASDAQ:GLBE) reported a pivotal shift in its financial performance for the first quarter of 2026, swinging to a GAAP net profit as its cross-border e-commerce platform captured a record volume of international trade.

Zenas BioPharma (NASDAQ:ZBIO) announced that it is on track to transition into a commercial-stage company, with plans to submit its first Biologics License Application (BLA) to the U.S. Food and Drug Administration this quarter.

Atour Lifestyle Holdings (NASDAQ:ATAT) reported a robust start to fiscal year 2026, delivering triple-digit profit momentum and aggressive top-line growth.

National Vision Holdings (NASDAQ:EYE) delivered a sharp increase in profitability for the first quarter of 2026, as successful pricing initiatives and a shift toward managed care customers bolstered the company’s bottom line.

Boyd Group Services (NYSE:BGSI) delivered record-breaking financial results for the first quarter of 2026, as the company reaped the initial benefits of its transformative $1.3 billion acquisition of Joe Hudson’s Collision Center.

Regis Corporation (NASDAQ:RGS) demonstrated improved operational efficiency in its third fiscal quarter, reporting a significant rise in net income and earnings per share despite a contraction in its top-line revenue.

WeRide (NASDAQ:WRD) reported record unaudited financial results for the first quarter of 2026, as the company’s aggressive international expansion into fare-charging robotaxi services began to scale.

Birkenstock Holding (NYSE:BIRK) revealed a surge in quarterly sales that matched its aggressive growth ambitions, though bottom-line results were pinched by escalating trade costs and unfavorable currency movements.

Alibaba Group Holding (NYSE:BABA) reported a complex set of financial results for the quarter and fiscal year ended March 31, 2026, revealing a company in the midst of an expensive strategic pivot.

UCloudlink Group (NASDAQ:UCL) recorded a contraction in its financial performance for the first quarter of 2026, marked by declining top-line revenue and a return to negative adjusted earnings.

Kyivstar (NASDAQ:KYIV) reported a robust start to fiscal year 2026, characterized by a significant acceleration in digital service adoption and strong double-digit growth across its core financial metrics.

Takeda Pharmaceutical (NYSE:TAK) reported fiscal year 2025 results that met its revised management guidance, as the company utilized aggressive operational savings to buffer the impact of generic competition for its top-selling ADHD medication, Vyvanse.